Thailand mentioned on Monday it can use AstraZeneca Plc’s COVID-19 vaccine as a second dose for individuals who acquired Sinovac’s shot as their first dose to extend safety in opposition to the illness.
The plan, if carried out, could be the primary publicly introduced combine and match of a Chinese language vaccine and a Western-developed shot. “That is to enhance safety in opposition to the Delta variant and construct excessive stage of immunity in opposition to the illness,” Well being Minister Anutin Charnvirakul advised reporters.
Thailand and neighbours like Indonesia have reported breakthrough infections amongst medical and frontline staff inoculated with Sinovac’s inactivated virus vaccine. The vast majority of Thailand’s medical and frontline staff got Sinovac’s pictures after February with the viral vector vaccine from AstraZeneca made extra broadly obtainable since June.
The announcement got here a day after Thailand’s well being ministry mentioned 618 medical staff out of 677,348 personnel who acquired two doses of Sinovac grew to become contaminated with COVID-19 from April to July. One nurse has died and one other medical employee is in essential situation. The nation plans to additionally give mRNA booster pictures to medical staff who acquired two pictures of the Sinovac vaccine.
Thailand recorded 8,656 infections and 80 deaths on Monday, among the many 345,027 instances and a pair of,791 fatalities total, the overwhelming majority from an outbreak since early April that’s being fueled by the extremely transmissible Alpha and Delta COVID-19 variants. It carried out its hardest coronavirus restrictions in additional than a yr on Monday in Bangkok and surrounding provinces, with new curbs on motion and gatherings imposed and widespread suspensions by airways and bus corporations.
The measures, initially for 2 weeks, intention to gradual the unfold of the coronavirus and embrace a curfew, mall closures and a five-person restrict on gatherings, after a interval of file or near-record deaths and instances.
(This story has not been edited by Devdiscourse employees and is auto-generated from a syndicated feed.)